|
|
| (40 tussenliggende versies worden niet weergegeven) |
| Regel 1: |
Regel 1: |
| - | In onderstaande tabel staat de geschiedenis per pagina van deze richtlijn vermeld:<br> | + | In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:<br> |
| | | | |
| - | {| width="100%" cellspacing="1" cellpadding="1" border="1" align="left" | + | {| width="100%" border="1" align="left" cellspacing="1" cellpadding="1" |
| | |- | | |- |
| | | valign="top" align="left" | '''Pagina'''<br> | | | valign="top" align="left" | '''Pagina'''<br> |
| - | | width="45" valign="top" align="left" | '''Datum eerste vaststelling'''<br> | + | | width="45" valign="top" align="left" | '''Link naar andere richtlijn''' |
| - | | width="45" valign="top" align="left" | '''Datum ongewijzigde verlenging'''<br>
| + | |
| - | | width="45" valign="top" align="left" | '''Datum tekstuele aanpassing'''<br>
| + | |
| - | | width="45" valign="top" align="left" | '''Datum inhoudelijke aanpassing'''<br>
| + | |
| - | | valign="top" align="left" | '''Opmerkingen'''<br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | '''[[Richtlijn HIV|Hoofdpagina (=inhoudsopgave)]]<br>''' | + | | valign="top" align="left" | [[Inhoud|'''Inhoud''']] |
| - | | width="45" valign="top" align="left" | 31-08-2010
| + | | width="45" valign="top" align="left" | SOA richtlijn<br>PrEP richtlijn |
| - | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" |
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011*
| + | |
| - | | valign="top" align="left" | * Aanpassing titel hoofdstuk 16
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn en inleiding]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Procedure herziening]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Samenstelling kernwerkgroep]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Overzicht belangen werkgroepleden]]
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011*<br>
| + | |
| - | | valign="top" align="left" | Update belangen werkgroepleden
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Definities]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | Geschiedenis per pagina van deze richtlijn (= huidige pagina)<br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | '''[[Hoofdstuk 2. Therapie bij volwassenen]]<br>''' | | | valign="top" align="left" | '''[[Hoofdstuk 2. Therapie bij volwassenen]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | <br> |
| - | | width="45" valign="top" align="left" | 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011*<br>
| + | |
| - | | valign="top" align="left" | * Aanpassing titel 2.4<br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[2.1. Wanneer beginnen?]] <br> | | | valign="top" align="left" | [[2.1. Wanneer beginnen?]] <br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Onderbouwing wanneer starten]]<br> | + | | valign="top" align="left" | [[2.2. Keuze van antiretrovirale therapie bij naïeve volwassenen met hiv|2.2. Keuze van anti-retrovirale therapie bij naïeve volwassenen met hiv]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Literatuur 2.1]]<br> | + | | valign="top" align="left" | [[2.3. Tijdelijk onderbreken van antiretrovirale therapie|2.3. Tijdelijk onderbreken van anti-retrovirale therapie]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[2.2. Keuze van antiretrovirale therapie bij naïeve volwassen patiënten]]<br> | + | | valign="top" align="left" | [[2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv|2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | 16-09-2011*<br>
| + | |
| - | | valign="top" align="left" | * Aanpassing i.v.m. kostenoverweging<br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Literatuur 2.2]]<br> | + | | valign="top" align="left" | '''[[Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen|Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen]]''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>Kinderformularium |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[2.3. Tijdelijk onderbreken van HAART]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[T½ van antiretrovirale middelen]]
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde patiënten]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011*<br>
| + | |
| - | | valign="top" align="left" | * Aanpassing titel hoofdstuk<br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 3. Behandeling van HIV-1 infectie bij kinderen]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>''' | | | valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[4.1. Controles HIV-patiënten (polikliniek)]] <br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Bij eerste consult bij HIV-seropositieve patiënt (polikliniek)]]
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" |
| + | |
| - | | width="45" valign="top" align="left" |
| + | |
| - | | valign="top" align="left" |
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Bij instellen op antiretrovirale therapie (polikliniek)]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Eerste controle na instellen op anti-retrovirale therapie 4-6 weken na start (polikliniek)]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Controle van patiënten op antiretrovirale therapie (polikliniek)]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Controle van patiënten zonder antiretrovirale therapie (polikliniek)]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[4.2. Spiegelbepaling]]<br> | | | valign="top" align="left" | [[4.2. Spiegelbepaling]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>TDM-protocollen |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 15-08-2011*<br>
| + | |
| - | | valign="top" align="left" | * Verwijzing naar nieuwe DHHS richtlijnen<br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br> | | | valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | <br>
| + | | valign="top" align="left" | '''[[Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie|Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie]]<br>''' |
| - | | width="45" valign="top" align="left" | <br>
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 5. Diagnostiek en behandeling primaire HIV-infectie]]<br>''' | + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 6. Therapietrouw bevorderende maatregelen]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[6.1. Therapietrouw beïnvloedende factoren]] <br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Literatuur 6.1]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[6.2. Therapietrouw bevorderende interventies]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Onderbouwing therapietrouw bevorderende interventies]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Literatuur 6.2]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | '''[[Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode]]<br>''' | | | valign="top" align="left" | '''[[Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH Perinatal<br> Landelijk hiv expositie protocol neonaten |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 01-06-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | 26-09-2011*<br>
| + | |
| - | | valign="top" align="left" | * Verwijzing nieuwe Amerikaanse richtlijn toegevoegd<br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Literatuur 7]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011*<br>
| + | |
| - | | valign="top" align="left" | * Toevoeging dosering medicatie<br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | '''[[Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring]]<br>''' | | | valign="top" align="left" | '''[[Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | 13-04-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Literatuur 8]]<br> | + | | valign="top" align="left" | '''[[Hoofdstuk 9. Bijzondere omstandigheden]]''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | <br> | + | | valign="top" align="left" | [[9.5. Adviezen m.b.t. gebruik anti-hiv middelen door de sonde]] |
| - | | width="45" valign="top" align="left" | <br> | + | | width="45" valign="top" align="left" | EACS |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | '''[[Hoofdstuk 9. Bijzondere omstandigheden]]<br>''' | + | | valign="top" align="left" | [[9.6. Doseringen bij gestoorde leverfunctie]] |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | EACS |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[9.1. Adviezen m.b.t. inname van anti-HIV middelen na braken]]<br> | + | | valign="top" align="left" | [[9.7. Doseringen bij gestoorde nierfunctie]] |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | EACS |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[9.2. Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment]]<br> | + | | valign="top" align="left" | '''[[Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1|Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | | width="45" valign="top" align="left" | <br> |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[9.3. Marge tussen twee innames]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[9.4. Inname medicatie bij overschrijden tijdzones]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[9.5. Adviezen m.b.t. gebruik anti-HIV middelen door de sonde]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[9.6. Doseringen bij gestoorde lever- en nierfunctie]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij HIV-1 positieve patiënten]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[10.1. Hepatitis B]]<br> | | | valign="top" align="left" | [[10.1. Hepatitis B]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>EACS |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011*<br>
| + | |
| - | | valign="top" align="left" | * Verwijzing naar nieuwe richtlijn<br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[10.2. Hepatitis C (acuut)|10.2. Hepatitis C (acuut)]]<br> | + | | valign="top" align="left" | [[10.2. Hepatitis C|10.2. Hepatitis C]] |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | HCV richtsnoer |
| - | | width="45" valign="top" align="left" | 14-12-2010
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011*<br>
| + | |
| - | | valign="top" align="left" | * Verwijzing naar nieuwe literatuur<br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Levels of evidence]]<br> | + | | valign="top" align="left" | [[10.3. HCC surveillance|10.3. HCC surveillance]] |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | HBV richtsnoer |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Literatuur 10.2]]<br> | + | | valign="top" align="left" | '''[[Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie|Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | | width="45" valign="top" align="left" | KNCV |
| - | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011*<br>
| + | |
| - | | valign="top" align="left" | *Verwijzing naar nieuwe literatuur<br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[10.3. Hepatitis C (chronisch)|10.3. Hepatitis C (chronisch)]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011<br> | + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011*<br>
| + | |
| - | | valign="top" align="left" | * Link naar nieuwe richtlijn<br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 11. Behandeling van tuberculose bij patiënten met een HIV-infectie]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Literatuur 11]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | '''[[Hoofdstuk 12. Comorbiditeit en bijwerkingen]]<br>''' | | | valign="top" align="left" | '''[[Hoofdstuk 12. Comorbiditeit en bijwerkingen]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | EACS<br> |
| - | | width="45" valign="top" align="left" | 14-12-2010
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011*<br>
| + | |
| - | | valign="top" align="left" | * Verwijzing naar nieuwe richtlijn<br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | <br> | + | | valign="top" align="left" | '''[[Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten|Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten]] <br>''' |
| - | | width="45" valign="top" align="left" | <br>
| + | | width="45" valign="top" align="left" | Aidsinfo NIH |
| - | | width="45" valign="top" align="left" | <br> | + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | '''[[Hoofdstuk 13. Screening van HIV-patiënten op anogenitale maligniteiten]] <br>''' | + | | valign="top" align="left" | [[Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie|'''Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie''']] |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>Nationale Antibioticaboekje<br>SWAB richtlijnen |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Onderbouwing screening van HIV-patiënten op anogenitale maligniteiten]]<br>
| + | | valign="top" align="left" | '''[[Hoofdstuk 16. Transmissiereductie (PEP)|Hoofdstuk 16. Transmissiemanagement]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | | width="45" valign="top" align="left" | <br> |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Literatuur 13]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 14. Interacties]]<br>''' | + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 <br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig sexueel contact
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 26-05-201*
| + | |
| - | | valign="top" align="left" | * Pagina opgeheven. Hiervoor in de plaats: <br>
| + | |
| - | [[Hoofdstuk 16. Transmissiereductie (PEP)]] | + | |
| - | | + | |
| - | |- | + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 16. Transmissiereductie (PEP)]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011<br> | + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 21-11-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[16.1. Prikaccidenten]]<br> | | | valign="top" align="left" | [[16.1. Prikaccidenten]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | LCI |
| - | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 26-05-2011*<br>
| + | |
| - | | valign="top" align="left" | * Wijziging hoofdstuk, met verwijzing naar richtlijn LCI<br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[16.2. Seksaccidenten]]<br> | | | valign="top" align="left" | [[16.2. Seksaccidenten]]<br> |
| - | | width="45" valign="top" align="left" | 26-05-2011<br> | + | | width="45" valign="top" align="left" | LCI/RIVM |
| - | | width="45" valign="top" align="left" | 21-11-2011<br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | '''[[Hoofdstuk 17. Vaccinatiebeleid]]<br>''' | | | valign="top" align="left" | '''[[Hoofdstuk 17. Vaccinatiebeleid]]<br>''' |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | <br> |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[17.1. Vaccinaties bij HIV-geïnfecteerde kinderen]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[17.2. Vaccinatie tegen influenza]] <br> | | | valign="top" align="left" | [[17.2. Vaccinatie tegen influenza]] <br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | RIVM<br>NHG |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Onderbouwing Vaccinatie tegen influenza]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Literatuur 17.2]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[17.3. Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) (Pneumokokken)]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | [[Literatuur 17.3]]<br>
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| | | valign="top" align="left" | [[17.4. Vaccinaties tegen Hepatitis A en B]]<br> | | | valign="top" align="left" | [[17.4. Vaccinaties tegen Hepatitis A en B]]<br> |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | RIVM |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[17.5. Vaccinatie bij HIV-geïnfecteerde reizigers]]<br> | + | | valign="top" align="left" | [https://richtlijnhiv.nvhb.nl/index.php/Addendum:%C2%A0SOA-richtlijn '''Addendum:''' SOA-richtlijn] |
| - | | width="45" valign="top" align="left" | 31-08-2010<br> | + | | width="45" valign="top" align="left" | SOA richtlijn |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| | |- | | |- |
| - | | valign="top" align="left" | [[Bureau's voor reizigersadvisering]]<br> | + | | valign="top" align="left" | [http://richtlijnhiv.nvhb.nl/images/2/22/PrEP-richtlijn-Nederland-8-september-2016-met-logos.pdf '''Addendum:''' Pre-exposure profylaxe (PrEP) richtlijn] |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | | width="45" valign="top" align="left" | PrEP-richtlijn |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | valign="top" align="left" | <br>
| + | |
| - | |-
| + | |
| - | | valign="top" align="left" | '''[[Hoofdstuk 18. Kostenoverzicht antiretrovirale middelen]]<br>'''
| + | |
| - | | width="45" valign="top" align="left" | 31-08-2010<br>
| + | |
| - | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | + | |
| - | | width="45" valign="top" align="left" | <br>
| + | |
| - | | width="45" valign="top" align="left" | 16-09-2011*<br>
| + | |
| - | | valign="top" align="left" | * Opname tabel kosten HIV combinaties<br>
| + | |
| | |} | | |} |
| - |
| |
| - | <span style="background-color: rgb(255, 255, 0);">Vervallen?:
| |
| - | </span>
| |
| - |
| |
| - | *[[Negatieve detuned ELISA|<span style="background-color: rgb(255, 255, 0);">Negatieve detuned ELISA</span>]]
| |
| - | *[[2.4. Richtlijnen bij salvage therapie|<span style="background-color: rgb(255, 255, 0);">2.4. Richtlijnen bij salvage therapie</span>]]<br>
| |
| - |
| |
| - | In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd:
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | {| width="100%" cellspacing="0" cellpadding="0" border="1" class="MsoTableGrid" style="mso-yfti-irow:0;mso-yfti-firstrow:yes"
| |
| - | |-
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''Pagina'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border:solid windowtext 1.0pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''Verwijzing naar andere richtlijnen'''
| |
| - |
| |
| - | |- style="mso-yfti-irow:1"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Richtlijn%20HIV">Hoofdpagina''' '''(=inhoudsopgave)</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span style="mso-bidi-font-weight:bold">
| |
| - | </span>
| |
| - |
| |
| - | |- style="mso-yfti-irow:2"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span style="mso-bidi-font-weight:bold">
| |
| - | </span>
| |
| - |
| |
| - | |- style="mso-yfti-irow:3"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%201.%20Achtergrondinformatie%20bij%20de%20ontwikkeling%20en%20herziening%20van%20deze%20richtlijn%20en%20inleiding">Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn''' '''en inleiding</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
| |
| - |
| |
| - | |- style="mso-yfti-irow:4"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Procedure%20herziening">Procedure herziening</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | NVHB Richtlijn 2007
| |
| - |
| |
| - | |- style="mso-yfti-irow:5"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Samenstelling%20kernwerkgroep">Samenstelling kernwerkgroep</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:6"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Overzicht%20belangen%20werkgroepleden">Overzicht belangen werkgroepleden</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:7"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Definities">Definities</a>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:8"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | Geschiedenis per pagina van deze richtlijn (= huidige pagina)
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:9"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:10"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%202.%20Therapie%20bij%20volwassenen">Hoofdstuk''' '''2. Therapie bij volwassenen</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:11"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.1.%20Wanneer%20beginnen?">2.1. Wanneer beginnen?</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:12"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20wanneer%20starten">Onderbouwing wanneer starten</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| |
| - |
| |
| - | |- style="mso-yfti-irow:13"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.1">Literatuur 2.1</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:14"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.2.%20Keuze%20van%20antiretrovirale%20therapie%20bij%20na%C3%AFeve%20volwassen%20pati%C3%ABnten">2.2. Keuze van antiretrovirale therapie bij naïeve volwassen patiënten</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| |
| - |
| |
| - | |- style="mso-yfti-irow:15"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.2">Literatuur 2.2</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:16"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.3.%20Tijdelijk%20onderbreken%20van%20HAART">2.3. Tijdelijk onderbreken van HAART</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| |
| - |
| |
| - | |- style="mso-yfti-irow:17"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/T%C2%BD%20van%20antiretrovirale%20middelen">T½ van antiretrovirale middelen</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:18"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.4.%20Richtlijn%20anti-retrovirale%20therapie%20bij%20voorbehandelde%20pati%C3%ABnten">2.4. Richtlijn <span class="SpellE">anti-retrovirale</span> therapie bij <span class="SpellE">voorbehandelde</span> patiënten</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
| |
| - |
| |
| - | |- style="mso-yfti-irow:19"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <o:p> </o:p>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:20"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%203.%20Behandeling%20van%20HIV-1%20infectie%20bij%20kinderen">Hoofdstuk''' '''3. Behandeling van HIV-1 infectie bij kinderen</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:21"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:22"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%204.%20Monitoring">Hoofdstuk''' '''4. Monitoring</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:23"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.1.%20Controles%20HIV-pati%C3%ABnten%20%28polikliniek%29">4.1. Controles HIV-patiënten (polikliniek)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:24"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20eerste%20consult%20bij%20HIV-seropositieve%20pati%C3%ABnt%20%28polikliniek%29">Bij eerste consult bij <span class="SpellE">HIV-seropositieve</span> patiënt (polikliniek)</a><a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20instellen%20op%20antiretrovirale%20therapie%20%28polikliniek%29" _fcknotitle=true _fcksavedurl="Bij instellen op antiretrovirale therapie (polikliniek)">Bij instellen op antiretrovirale therapie (polikliniek)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:25"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Eerste%20controle%20na%20instellen%20op%20anti-retrovirale%20therapie%204-6%20weken%20na%20start%20%28polikliniek%29">Eerste controle na instellen op <span class="SpellE">anti-retrovirale</span> therapie 4-6 weken na start (polikliniek)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:26"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20op%20antiretrovirale%20therapie%20%28polikliniek%29">Controle van patiënten op antiretrovirale therapie (polikliniek)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:27"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20zonder%20antiretrovirale%20therapie%20%28polikliniek%29">Controle van patiënten zonder antiretrovirale therapie (polikliniek)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:28"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.2.%20Spiegelbepaling">4.2. Spiegelbepaling</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:29"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.3.%20Resistentiebepalingen">4.3. Resistentiebepalingen</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:30"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:31"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%205.%20Diagnostiek%20en%20behandeling%20primaire%20HIV-infectie">Hoofdstuk''' '''5. Diagnostiek en behandeling primaire <span class="SpellE">HIV-infectie</span></a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:32"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:33"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%206.%20Therapietrouw%20bevorderende%20maatregelen">Hoofdstuk''' '''6. Therapietrouw bevorderende maatregelen</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:34"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.1.%20Therapietrouw%20be%C3%AFnvloedende%20factoren">6.1. Therapietrouw beïnvloedende factoren</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:35"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.1">Literatuur 6.1</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:36"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.2.%20Therapietrouw%20bevorderende%20interventies">6.2. Therapietrouw bevorderende interventies</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:37"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20therapietrouw%20bevorderende%20interventies">Onderbouwing therapietrouw bevorderende interventies</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:38"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.2">Literatuur 6.2</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:39"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:40"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%207.%20Preventie%20van%20moeder-kind%20overdracht:%20zwangerschap,%20bevalling%20en%20neonatale%20periode">Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale''' '''periode</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
| |
| - | NIH Perinatal</span>
| |
| - |
| |
| - | <span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
| |
| - |
| |
| - | |- style="mso-yfti-irow:41"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%207">Literatuur 7</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:42"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <o:p> </o:p>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:43"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%208.%20HIV-2%20bij%20volwassenen:%20Behandeling%20en%20monitoring">Hoofdstuk''' '''8. HIV-2 bij volwassenen: Behandeling en monitoring</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
| |
| - | NIH</span>
| |
| - |
| |
| - | |- style="mso-yfti-irow:44"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%208">Literatuur 8</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:45"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:46"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%209.%20Bijzondere%20omstandigheden">Hoofdstuk''' '''9. Bijzondere omstandigheden</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:47"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.1.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20na%20braken">9.1. Adviezen m.b.t. inname van anti-HIV middelen na braken</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:48"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.2.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20bij%20vergeten%20van%20slikmoment">9.2. Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:49"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.3.%20Marge%20tussen%20twee%20innames">9.3. Marge tussen twee innames</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:50"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.4.%20Inname%20medicatie%20bij%20overschrijden%20tijdzones">9.4. Inname medicatie bij overschrijden tijdzones</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:51"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.5.%20Adviezen%20m.b.t.%20gebruik%20anti-HIV%20middelen%20door%20de%20sonde">9.5. Adviezen m.b.t. gebruik anti-HIV middelen door de sonde</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:52"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.6.%20Doseringen%20bij%20gestoorde%20lever-%20en%20nierfunctie">9.6. Doseringen bij gestoorde lever- en nierfunctie</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:53"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:54"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2010.%20Behandeling%20van%20hepatitis%20B/C-virus%20co%C3%AFnfectie%20bij%20HIV-1%20positieve%20pati%C3%ABnten">Hoofdstuk 10. Behandeling van hepatitis B/C-virus <span class="SpellE">coïnfectie</span>''' '''bij HIV-1 positieve patiënten</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:55"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.1.%20Hepatitis%20B"><span lang="EN-US" style="mso-ansi-language:EN-US">10.1. Hepatitis B</span></a><span lang="EN-US" style="mso-ansi-language:EN-US"><o:p></o:p></span>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | EACS
| |
| - |
| |
| - | |- style="mso-yfti-irow:56"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.2.%20Hepatitis%20C%C2%A0%28acuut%29"><span lang="EN-US" style="mso-ansi-language:EN-US">10.2. Hepatitis C (<span class="SpellE">acuut</span>)</span></a><span lang="EN-US" style="mso-ansi-language: EN-US"><o:p></o:p></span>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | NL aanbevelingen
| |
| - |
| |
| - | NEAT
| |
| - |
| |
| - | |- style="mso-yfti-irow:57"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Levels%20of%20evidence"><span lang="EN-US" style="mso-ansi-language:EN-US">Levels of evidence</span></a><span lang="EN-US" style="mso-ansi-language:EN-US"><o:p></o:p></span>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:58"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2010.2">Literatuur 10.2</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:59"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.3.%20Hepatitis%20C%C2%A0%28chronisch%29">10.3. Hepatitis C (chronisch)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | EACS
| |
| - |
| |
| - | |- style="mso-yfti-irow:60"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <o:p> </o:p>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <br>
| |
| - |
| |
| - | |- style="mso-yfti-irow:61"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2011.%20Behandeling%20van%20tuberculose%20bij%20pati%C3%ABnten%20met%20een%20HIV-infectie">Hoofdstuk''' '''11. Behandeling van tuberculose bij patiënten met een HIV-<span class="SpellE">infectie</span></a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:62"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2011">Literatuur 11</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:63"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <o:p> </o:p>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:64"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2012.%20Comorbiditeit%20en%20bijwerkingen">Hoofdstuk''' '''12. Comorbiditeit en bijwerkingen</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <span style="mso-bidi-font-weight:bold">EACS</span>
| |
| - |
| |
| - | |- style="mso-yfti-irow:65"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:66"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2013.%20Screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten">Hoofdstuk''' '''13. Screening van HIV-patiënten op anogenitale maligniteiten</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:67"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten">Onderbouwing screening van HIV-patiënten op anogenitale maligniteiten</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:68"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2013">Literatuur 13</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:69"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:70"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2014.%20Interacties">Hoofdstuk''' '''14. Interacties</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:71"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:72"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2015.%20Profylaxe%20en%20behandeling%20van%20opportunistische%20infectie">Hoofdstuk''' '''15. Profylaxe en behandeling van opportunistische infectie</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:73"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <o:p> </o:p>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:74"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig <span class="SpellE">sexueel</span> contact
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:75"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2016.%20Transmissiereductie%20%28PEP%29">Hoofdstuk''' '''16. <span class="GramE">Transmissiereductie</span> (PEP)</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:76"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.1.%20Prikaccidenten">16.1. Prikaccidenten</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | LCI
| |
| - |
| |
| - | |- style="mso-yfti-irow:77"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.2.%20Seksaccidenten">16.2. Seksaccidenten</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | LCI/RIVM
| |
| - |
| |
| - | |- style="mso-yfti-irow:78"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:79"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2017.%20Vaccinatiebeleid">Hoofdstuk''' '''17. Vaccinatiebeleid</a><o:p></o:p>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:80"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.1.%20Vaccinaties%20bij%20HIV-ge%C3%AFnfecteerde%20kinderen">17.1. Vaccinaties bij <span class="SpellE">HIV-geïnfecteerde</span> kinderen</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | CDC
| |
| - |
| |
| - | |- style="mso-yfti-irow:81"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.2.%20Vaccinatie%20tegen%20influenza">17.2. Vaccinatie tegen influenza</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | NHG Standaard
| |
| - |
| |
| - | |- style="mso-yfti-irow:82"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20influenza">Onderbouwing Vaccinatie tegen influenza</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:83"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.2">Literatuur 17.2</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:84"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.3.%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29">17.3. Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:85"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29%20%28Pneumokokken%29">Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) (Pneumokokken)</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:86"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.3">Literatuur 17.3</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:87"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.4.%20Vaccinaties%20tegen%20Hepatitis%20A%20en%20B">17.4. Vaccinaties tegen Hepatitis A en B</a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:88"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a
| |
| - |
| |
| - | href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.5.%20Vaccinatie%20bij%20HIV-ge%C3%AFnfecteerde%20reizigers">17.5. Vaccinatie bij <span class="SpellE">HIV-geïnfecteerde</span><span class="SpellE">reizigers</span></a>
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | LCR
| |
| - |
| |
| - | CDC
| |
| - |
| |
| - | |- style="mso-yfti-irow:89"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | <a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bureau%27s%20voor%20reizigersadvisering"><span class="SpellE">Bureau's</span> voor reizigersadvisering</a>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:90"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<o:p> </o:p>'''
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |- style="mso-yfti-irow:91;mso-yfti-lastrow:yes"
| |
| - | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | '''<a'''
| |
| - |
| |
| - | '''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2018.%20Kostenoverzicht%20antiretrovirale%20middelen">Hoofdstuk''' '''18. Kostenoverzicht antiretrovirale middelen</a>'''
| |
| - |
| |
| - | <br>
| |
| - |
| |
| - | | width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
| |
| - | |}
| |
| - |
| |
| - | <o:p> </o:p> </div> </body></html>
| |
In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:
